Elias J. Anaissie

Elias J. Anaissie's AcademicInfluence.com Rankings

Elias J. Anaissie

Philosophy

#5112

World Rank

#7838

Historical Rank

Logic

#2443

World Rank

#3434

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Elias J. Anaissie's Degrees

Masters Microbiology University of Cincinnati

Why Is Elias J. Anaissie Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Elias J. Anaissie's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. (2008) (2526)
Antitumor activity of thalidomide in refractory multiple myeloma. (1999) (2498)
Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. (2010) (1246)
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). (2010) (1214)
The molecular classification of multiple myeloma. (2006) (1012)
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. (2002) (943)
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. (2009) (911)
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. (2006) (839)
Fusarium Infections in Immunocompromised Patients (2007) (813)
The epidemiology of hematogenous candidiasis caused by different Candida species. (1997) (793)
Thalidomide and hematopoietic-cell transplantation for multiple myeloma. (2006) (731)
Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. (2009) (724)
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. (2002) (662)
Taxonomy, biology, and clinical aspects of Fusarium species (1994) (652)
Total therapy with tandem transplants for newly diagnosed multiple myeloma. (1999) (617)
Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. (1998) (614)
Infections due to emerging and uncommon medically important fungal pathogens. (2004) (576)
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. (2001) (553)
Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. (1997) (552)
Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. (1993) (545)
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. (2001) (499)
A Randomized, Double-Blind Comparative Trial Evaluating the Safety of Liposomal Amphotericin B versus Amphotericin B Lipid Complex in the Empirical Treatment of Febrile Neutropenia (2000) (496)
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. (2009) (454)
Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. (2002) (395)
Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients (2010) (388)
Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. (1992) (382)
The hospital water supply as a source of nosocomial infections: a plea for action. (2002) (376)
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. (2007) (374)
Revisiting the source of candidemia: skin or gut? (2001) (368)
Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. (1999) (364)
Safety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome) in Patients Infected withAspergillus Species and Other Filamentous Fungi: Maximum Tolerated Dose Study (2001) (344)
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. (2000) (340)
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 (2007) (321)
Infections in Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine (1998) (313)
Predictors of adverse outcome in cancer patients with candidemia. (1998) (307)
Fusarium infection in hematopoietic stem cell transplant recipients. (2004) (306)
Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. (2001) (305)
Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. (2012) (296)
Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. (2009) (288)
Treatment of multiple myeloma. (2004) (283)
Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection (2003) (279)
Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. (1996) (279)
Factors associated with mortality in transplant patients with invasive aspergillosis. (2010) (277)
Results of autologous stem cell transplant in multiple myeloma patients with renal failure (2001) (275)
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. (2002) (253)
Invasive Non-Aspergillus Mold Infections in Transplant Recipients, United States, 2001–2006 (2011) (252)
New spectrum of fungal infections in patients with cancer. (1989) (250)
Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi (1995) (250)
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. (2008) (246)
Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. (1993) (243)
Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. (2002) (238)
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation (2004) (235)
Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. (2010) (228)
The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside. (1996) (219)
Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years (2001) (217)
Emerging and less common fungal pathogens. (2002) (212)
A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. (1992) (212)
Genetic Diversity of Human Pathogenic Members of the Fusarium oxysporum Complex Inferred from Multilocus DNA Sequence Data and Amplified Fragment Length Polymorphism Analyses: Evidence for the Recent Dispersion of a Geographically Widespread Clonal Lineage and Nosocomial Origin (2004) (212)
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. (2010) (205)
Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. (2003) (204)
Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. (1991) (204)
Detection of amphotericin B-resistant Candida isolates in a broth-based system (1995) (200)
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. (2001) (198)
Regulation of cryptococcal capsular polysaccharide by iron. (1993) (196)
International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia (2005) (196)
Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. (2002) (195)
High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2 (2010) (188)
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. (2007) (181)
Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. (1996) (181)
Importance of Candida species other than Candida albicans as opportunistic pathogens. (1998) (173)
Optimizing the Correlation between Results of Testing In Vitro and Therapeutic Outcome In Vivo for Fluconazole by Testing Critical Isolates in a Murine Model of Invasive Candidiasis (1998) (173)
Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. (1997) (170)
Should vascular catheters be removed from all patients with candidemia? An evidence-based review. (2002) (170)
Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. (2013) (169)
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2 (2008) (167)
Myeloma of the central nervous system: association with high‐risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations (2002) (160)
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization‐defined chromosome 13 deletion in multiple myeloma: early results of total therapy II (2003) (159)
Mobilization of CD34+ cells in elderly patients (≥ 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen (2003) (156)
Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma (2002) (156)
Primary Candida pneumonia. Experience at a large cancer center and review of the literature. (1993) (153)
Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications (2007) (152)
Improvement in the outcome of invasive fusariosis in the last decade. (2014) (151)
Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. (2008) (151)
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. (2011) (150)
Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care (1998) (146)
A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. (2000) (146)
Clinical activity of arsenic trioxide for the treatment of multiple myeloma (2002) (145)
Actiated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications (2002) (142)
Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans (1993) (142)
VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma (2008) (142)
Pharmacokinetics and Safety of Oral Posaconazole in Neutropenic Stem Cell Transplant Recipients (2006) (140)
Treatment of 21 Cases of Invasive Mucormycosis with Amphotericin B Colloidal Dispersion (2001) (134)
Outcome from mechanical ventilation after autologous peripheral blood stem cell transplantation. (2002) (132)
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. (2003) (129)
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. (2006) (129)
Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. (2001) (128)
Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. (1996) (127)
Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. (1993) (126)
Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. (1992) (126)
Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma (2008) (125)
Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. (1995) (125)
18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. (2005) (124)
Age Is Not a Prognostic Variable With Autotransplants for Multiple Myeloma (1999) (123)
Correlation between in vitro and in vivo activity of antifungal agents against Candida species. (1994) (122)
Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant (2004) (120)
Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B (1994) (120)
Mucosa or skin as source of coagulase-negative staphylococcal bacteraemia? (2004) (118)
Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. (1992) (117)
Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis (2007) (116)
Infections in patients with hematological cancer: recent developments. (2003) (115)
Emerging fungal pathogens (1989) (115)
Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma (2004) (114)
Probable invasive aspergillosis without prespecified radiologic findings: proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. (2010) (114)
Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients (2006) (112)
Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. (2009) (112)
Age is not a prognostic variable with autotransplants for multiple myeloma. (1999) (111)
Nosocomial aspergillosis is waterborne. (2001) (110)
Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation. (2009) (107)
Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal. (1995) (107)
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. (2010) (106)
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. (2008) (105)
Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling (2007) (100)
Do antimicrobial-impregnated central venous catheters prevent catheter-related bloodstream infection? (2003) (100)
Prospective study of religious coping among patients undergoing autologous stem cell transplantation (2009) (95)
Malignant pleural effusion of multiple myeloma: Prognostic factors and outcome (2005) (95)
Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. (2003) (94)
Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading (1991) (93)
Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. (2007) (92)
Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds. (2002) (91)
Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model (2006) (90)
Predicting long‐term (≥ 5 years) event‐free survival in multiple myeloma patients following planned tandem autotransplants (2002) (90)
Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. (1996) (90)
Diagnosis of deep septic thrombophlebitis in cancer patients by fluorine-18 fluorodeoxyglucose positron emission tomography scanning: a preliminary report. (2004) (89)
Nosocomial fungal infections. Old problems and new challenges. (1989) (85)
The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? (1998) (84)
Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method (1989) (83)
Fusarium. A newly recognized fungal pathogen in immunosuppressed patients (1986) (82)
Role of catheter colonization and infrequent hematogenous seeding in catheter-related infections (1995) (80)
Bacteremia due to Achromobacter xylosoxidans in patients with cancer. (1992) (80)
Effects of exercise in combination with epoetin alfa during high-dose chemotherapy and autologous peripheral blood stem cell transplantation for multiple myeloma. (2008) (79)
Prevention of fungal infections in the immunocompromised host. (2003) (79)
Aspergillus fumigatus conidia induce a Th1-type cytokine response. (1997) (78)
Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection (1995) (77)
Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies (1997) (77)
Bradycardia during therapy for multiple myeloma with thalidomide. (2004) (76)
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. (2008) (76)
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3 (2009) (74)
Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data (2013) (71)
Treatment of Murine Fusariosis with SCH 56592 (1999) (71)
High‐dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinaemia (1999) (68)
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease (2007) (66)
Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. A disease that is usually severe and complicated. (1996) (65)
Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients (1997) (65)
Early diagnosis of invasive pulmonary aspergillosis in hematologic patients: an opportunity to improve the outcome (2013) (65)
A Phase III, Randomized, Double-blind, Placebo-controlled, Multinational Trial of Iseganan for the Prevention of Oral Mucositis in Patients Receiving Stomatotoxic Chemotherapy (PROMPT-CT Trial) (2003) (63)
How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach. (2014) (63)
Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis (1994) (63)
The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management. (2004) (63)
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. (2001) (62)
Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. (2011) (61)
Infections due to Cunninghamella bertholletiae in patients with cancer: report of three cases and review. (1994) (61)
Pseudomonas putida. Newly recognized pathogen in patients with cancer. (1987) (61)
Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients. (1988) (61)
Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice (1997) (60)
Primary small intestinal lymphoma in adults. A comparative study of IPSID versus non‐IPSID in the middle east (1987) (59)
Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy. (2005) (59)
Immunomodulation with interferon‐gamma and colony‐stimulating factors for refractory fungal infections in patients with leukemia (2005) (57)
The role of immunoreconstitution in the management of refractory opportunistic fungal infections. (1998) (57)
A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. (2004) (56)
Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone (2000) (56)
Disseminated Geotrichum candidum infection (1987) (56)
Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia. (1992) (56)
Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony‐stimulating factor alone (2001) (56)
MicroRNA theragnostics for the clinical management of multiple myeloma (2014) (55)
Fungal infections in iatrogenically compromised hosts. (1998) (55)
Effects of exercise on fatigue, sleep, and performance: a randomized trial. (2012) (55)
Thalidomide in the management of multiple myeloma. (2001) (55)
Lack of activity of amphotericin B in systemic murine fusarial infection. (1992) (53)
Incidence of imipenem hypersensitivity reactions in febrile neutropenic bone marrow transplant patients with a history of penicillin allergy. (2000) (53)
Bisphosphonates and jaw osteonecrosis: The UAMS experience (2007) (51)
Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B (1991) (50)
Treatment of Invasive Fungal Infections in Renally Impaired Patients with Amphotericin B Colloidal Dispersion (1998) (50)
Diagnosis of infection of implantable central venous catheters by [18F]fluorodeoxyglucose positron emission tomography (2004) (50)
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics (2007) (49)
Emerging fungi. (2006) (46)
β‐Lactam regimens for the febrile neutropenic patient (1990) (46)
First thalidomide clinical trial in multiple myeloma: a decade. (2008) (46)
A model of sustained gastrointestinal colonization by Candida albicans in healthy adult mice (1990) (45)
Comparison of the efficacy of polyenes and triazoles against hematogenous Candida krusei infection in neutropenic mice. (1993) (45)
Predictors of outcome in cancer patients with candidemia. (2000) (44)
Trial design for mold-active agents: time to break the mold--aspergillosis in neutropenic adults. (2007) (43)
Effects of broad-spectrum antimicrobial agents on yeast colonization of the gastrointestinal tracts of mice (1990) (41)
Recent advances in the epidemiology, prevention and treatment of invasive fungal infections in neutropenic patients. (1994) (41)
Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. (2010) (41)
Optimizing Voriconazole Susceptibility Testing ofCandida: Effects of Incubation Time, Endpoint Rule, Species of Candida, and Level of Fluconazole Susceptibility (1999) (40)
Early detection of bone infection and differentiation from post‐surgical inflammation using 2‐deoxy‐2‐[18F]‐fluoro‐D‐glucose positron emission tomography (FDG‐PET) in an animal model (2005) (40)
Stenotrophomonas maltophilia infections. (2003) (40)
Central nervous system histoplasmosis. An unappreciated complication of the acquired immunodeficiency syndrome. (1988) (40)
Thalidomide in the management of multiple myeloma. (2001) (40)
Transplantation as salvage therapy for high-risk patients with myeloma in relapse (2002) (39)
Problems and controversies in the management of hematogenous candidiasis. (1996) (39)
International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols (2011) (38)
Malassezia and Trichosporon: two emerging pathogenic basidiomycetous yeast-like fungi. (1994) (38)
Collaborative investigation of broth microdilution and semisolid agar dilution for in vitro susceptibility testing of Candida albicans (1992) (36)
Eight‐year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1 (2008) (35)
Experimental hematogenous candidiasis caused by Candida krusei and Candida albicans: species differences in pathogenicity (1993) (35)
Pneumonia with cunninghamella species in patients with hematologic malignancies: A case report and review of the literature (1986) (35)
Stenotrophomonas maltophilia: an unusual cause of biliary sepsis. (1995) (35)
The Arkansas approach to therapy of patients with multiple myeloma. (2007) (35)
The new antifungal azoles: fluconazole and itraconazole (1994) (34)
Is it time to redefine the management of febrile neutropenia in cancer patients? (1995) (34)
Fungal Infections in Patients with Cancer (1990) (34)
Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study (1996) (34)
Erratum: Antitumor activity of thalidomide in refractory multiple myeloma (New England Journal of Medicine (November 18, 1999) 341 (1565-1571)) (2000) (33)
Stenotrophomonas maltophilia meningitis. Report of two cases and review of the literature. (1997) (32)
Infections in patients with multiple myeloma. (2009) (31)
Cytokines as therapy for opportunistic fungal infections. (1998) (31)
Colonization and molecular epidemiology of coagulase-negative Staphylococcal bacteremia in cancer patients: a pilot study. (2006) (31)
Bortezomib (Velcade™) + Adriamycin™ + Thalidomide + Dexamethasone (VATD) as an Effective Regimen in Patients with Refractory or Relapsed Multiple Myeloma (MM). (2004) (30)
Review ofCitrobacter bacteremia in cancer patients over a sixteen-year period (1991) (29)
Effectiveness of cisplatin in the treatment of anal squamous cell carcinoma. (1985) (29)
Granulocyte colony‐stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission (1993) (29)
Are antimicrobial-impregnated catheters effective? Replace the water and grab your washcloth, because we have a baby to wash. (2004) (29)
Characterizing and Predicting Amphotericin B‐Associated Nephrotoxicity in Bone Marrow or Peripheral Blood Stem Cell Transplant Recipients (2002) (29)
Experimental fusarial hyalohyphomycosis in a murine model. (1991) (28)
Fungal infections in hematopoietic stem cell transplantation and solid-organ transplantation--focus on aspergillosis. (2009) (28)
Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice (1994) (27)
Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients (2004) (27)
Baseline platelet count and creatinine clearance rate predict the outcome of neutropenia-related invasive aspergillosis. (2012) (27)
Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy (1999) (27)
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. (2009) (25)
Septic prepatellar bursitis caused by Stenotrophomonas (Xanthomonas) maltophilia. (1996) (24)
Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: counterpoint. (2008) (24)
Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection (1994) (23)
GWAS of 972 autologous stem cell recipients with multiple myeloma identifies 11 genetic variants associated with chemotherapy-induced oral mucositis (2015) (23)
Update on invasive candidiasis. (1997) (22)
Rituximab and intravenous immunoglobulin (IVIG) for the management of acquired factor VIII inhibitor in multiple myeloma: case report and review of literature (2011) (22)
Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients (2011) (21)
Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients (2006) (21)
Branhamella catarrhalis septicemia in patients with leukemia (1988) (21)
Addition of Bortezomib (Velcade™) to High Dose Melphalan (Vel-Mel) as an Effective Conditioning Regimen with Autologous Stem Cell Support in Multiple Myeloma (MM). (2004) (21)
γ-cyclodextrin: Testosterone complex suitable for sublingual administration (1987) (21)
New approaches to antifungal chemotherapy. (1998) (21)
Diagnosis and therapy of fungal infection in patients with leukemia--new drugs and immunotherapy. (2008) (20)
Effects of in vitro and in vivo cytokine treatment, leucapheresis and irradiation on the function of human neutrophils: implications for white blood cell transfusion therapy. (1997) (20)
Stenotrophomonas (Xanthomonas) maltophilia urinary tract infection. A disease that is usually severe and complicated (1996) (20)
Making progress in treating multiple myeloma with total therapies: issue of complete remission and more (2008) (19)
A novel murine model of disseminated trichosporonosis (1992) (19)
Beta-lactam regimens for the febrile neutropenic patient. (1990) (19)
Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1 (2012) (19)
Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer: experience with SCH 39304. (1993) (19)
Potential use of a simplified method for determination of itraconazole levels in plasma and esophageal tissue by using high-performance liquid chromatography (1995) (18)
Collection of peripheral blood stem cells after a preceding autograft: unfavorable effect of prior interferon-α therapy (1999) (18)
Serial measurement of serum C-reactive protein levels can identify patients at risk for severe complications following autologous stem cell transplantation (2005) (18)
A bad bug takes on a new role as a cause of ventilator-associated pneumonia. (2008) (17)
Iron acquisition by Cryptococcus neoformans. (1995) (17)
Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma. (2006) (17)
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. (2022) (17)
Elevated Expression of CKS1B at 1q21 Is Highly Correlated with Short Survival in Myeloma. (2004) (16)
Fusarium-caused hyalohyphomycosis: an overview. (1992) (16)
Activities of D0870, a novel triazole, against Candida lusitaniae and Trichosporon beigelii in experimental murine infections (1995) (16)
Suppression of abnormal karyotype predicts superior survival in multiple myeloma (2008) (16)
The clinical spectrum of stenotrophomonas (xanthomonas) maltophilia respiratory infection. (2000) (15)
Deep septic thrombophlebitis: an unrecognized cause of relapsing bacteremia in patients with cancer. (2004) (15)
Ninety Percent Sustained Complete Response (CR) Rate Projected 4 Years after Onset of CR in Gene Expression Profiling (GEP)-Defined Low-Risk Multiple Myeloma (MM) Treated with Total Therapy 3 (TT3): Basis for GEP-Risk-Adapted TT4 and TT5 (2008) (15)
Time of catheter removal in candidemia and mortality (2018) (14)
High‐dose melphalan‐based autotransplants for multiple myeloma (2008) (14)
Outpatient therapy for febrile neutropenia: who, when, and how? (1999) (14)
Invasive candidiasis during granulocytopenia. (1993) (14)
Protective Effect of VELCADE® on Thalidomide-Associated Deep Vein Thrombosis (DVT). (2004) (13)
Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients (2002) (13)
Tackling antibiotic resistance in febrile neutropenia: current challenges with and recommendations for managing infections with resistant Gram-negative organisms (2015) (13)
CHAPTER 7 – Antifungal therapy (2009) (13)
When a paradoxical increase in serum galactomannan antigen during caspofungin therapy is not paradoxical after all. (2007) (12)
Disseminated trichosporonosis: Meeting the challenge (1991) (12)
Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma (2008) (12)
Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience (2003) (12)
Reserpine in propranolol-resistant thyroid storm. (1985) (12)
Phase II Study of SU 5416 , a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor , in Patients with Refractory Multiple Myeloma (2004) (12)
Chronic systemic candidiasis (1989) (11)
Steady-State Pharmacokinetics of Oral Voriconazole and Its Primary Metabolite, N-Oxide Voriconazole, Pre- and Post-Autologous Peripheral Stem Cell Transplantation (2013) (11)
New emerging fungal pathogens (1995) (11)
Burkitt's lymphoma in the Middle East. (1985) (11)
Retrospective Analysis of Fractionated High-Dose Melphalan (F-MEL) and Bortezomib-Thalidomide-Dexamethasone (VTD) with Autotransplant (AT) Support for Advanced and Refractory Multiple Myeloma (AR-MM). (2006) (10)
Infection – an underappreciated cause of bone pain in multiple myeloma (2003) (10)
When to Start Antifungal Therapy in the Non-Neutropenic Critically III? (1996) (10)
Efficacy of continuous flucytosine infusion against Candida lusitaniae in experimental hematogenous murine candidiasis (1996) (10)
Preemptive intravenous immunoglobulin allows safe and timely administration of antineoplastic therapies in patients with multiple myeloma and parvovirus B19 disease (2013) (10)
Comparison of an assumption‐free Bayesian approach with Optimal Sampling Schedule to a maximum a posteriori Approach for Personalizing Cyclophosphamide Dosing (2014) (10)
Invasive Fusariosis in Patients with Hematologic Diseases (2021) (10)
Fungal infections in the immunocompromised patient (2005) (10)
Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation (2018) (10)
Making progress in treating multiple myeloma with total therapies: issue of complete remission and more (2008) (10)
Distinguishing the Causes of Pulmonary Infiltrates in Patients With Acute Leukemia. (2015) (10)
Total Therapy 3 (TT3) Incorporating VelcadeR (V) Intro Upfront Management of Multiple Myeloma (MM): Comparison with TT2 + Thalidomide (T). (2005) (9)
Two-site comparison of broth microdilution and semisolid agar dilution methods for susceptibility testing of Cryptococcus neoformans in three media (1993) (9)
Effects of cyclophosphamide and ceftriaxone on gastrointestinal colonization of mice by Candida albicans (1996) (9)
CHAPTER 13 – Hyalohyphomycosis (2009) (8)
Results of total therapy 2 (TT 2), a phase III randomized trial, to determine the role of thalidomide (THAL) in the upfront management of multiple myeloma (MM) (2005) (8)
Introduction: Immunomodulation for the Treatment of Invasive Fungal Infections (1998) (8)
Diagnostic Imaging of Multiple Myeloma - FDG PET and MRI Complementary for Tracking Short Vs. Long Term Tumor Response. (2004) (8)
Recurrent spontaneous gastrointestinal graft-versus-host disease in autologous hematopoietic stem cell transplantation. (2010) (8)
Prevention of Infections in Patients with Hematological Malignancies (2012) (8)
High-dose chemotherapy and autologous stem cell transplantation for multiple myeloma in HIV-positive patients in the highly active antiretroviral therapy era: the myeloma institute of research and therapy experience. (2013) (8)
An Update on the Role of Thalidomide (THAL) in Total Therapy 2 (TT2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Analysis of Subgroups Defined by Standard Prognostic Factors (SPF) and Gene Expression Profiling (GEP)-Derived Subgroups. (2006) (8)
Fungal infection caused by Fusarium in cancer patients. (1987) (7)
Validation of Serum Aspergillus Galactomannan Index as a Surrogate Endpoint for Outcome of Invasive Aspergillosis: Clinical and Research Implications. (2006) (7)
Chapter 20 – Invasive fungal infections in cancer patients (2009) (7)
Infections in chronic leukemias and other hematological malignancies (2003) (7)
Final analysis of the phase II, randomized, double-blind, placebo-controlled trial of single dose velafermin (CG53135-05) for the prevention of oral mucositis. (2006) (7)
Antifungal therapy. (2020) (7)
Fusarium and the immunocompromised host: liaisons dangeureuses. (1990) (7)
Fluconazole Susceptibility Testing of Candida albicans: Microtiter Method That Is Independent of Inoculum Size, Temperature, and Time of Reading (1992) (7)
High CR and near-CR rate with bortezomib incorporated into up-front therapy of multiple myeloma with tandem transplants. (2006) (7)
CHAPTER 17 – Pneumocystis (2009) (6)
Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. (2006) (6)
Future directions in the clinical management of amyloid light-chain amyloidosis (2014) (6)
Total Therapy 2 (TT2) for Multiple Myeloma (MM): Thalidomide (T) Effects Superior Complete Response (CR) and Event-Free Survival (EFS); Similar Overall Survival (OS) Linked to Shorter Post-Relapse Survival. (2005) (6)
Phase II study of total therapy 3 (TT3) with added bortezomib (V) for multiple myeloma (MM) (2007) (6)
Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high‐risk gene expression profile (2009) (6)
The surgical management of abdominal pain in the multiple myeloma patient. (2012) (6)
CHAPTER 8 – Candida (2009) (6)
SCH 51048, a new antifungal triazole active against hematogenous Candida krusei infections in neutropenic mice (1995) (6)
Comparing Toxicities and Survival Outcomes with Total Therapy 4 (TT4) for 70-Gene (R70)-Defined Low-Risk Multiple Myeloma (MM) to Results Obtained with Total Therapy 3 Protocols TT3A and TT3B (2010) (6)
FDG PET Functional Imaging in Multiple Myeloma - Clinically Important Caveats, Pitfalls, and Pearls. (2004) (5)
Activated lymphocytes reduce adherence of Aspergillus fumigatus. (1998) (5)
Antimicrobial coating of central venous catheters: show me the data. (2007) (5)
Deficiency of Mannose-Binding Lectin Is a Risk Factor for Invasive Pulmonary Aspergillosis in Patients with Multiple Myeloma: An Analysis of 482 Patients (2008) (5)
Total therapy (TT) for myeloma (MM)—10% cure rate with TT1 suggested by >10yr continuous complete remission (CCR): Bortezomib in TT3 overcomes poor-risk associated with T(4;14) and DelTP53 in TT2 (2008) (5)
Candidemia in patients with cancer: are persistent neutropenia and severity of illness score still relevant? (2005) (5)
Integration of DNA Copy Number and Gene Expression Alterations Reveal Novel Insights into the Molecular Pathogenesis and Prognosis of Multiple Myeloma (2008) (5)
Changes in the Expression of Proteasome Genes in Tumor Cells Following Short-Term Proteasome Inhibitor Therapy Predicts Survival in Multiple Myeloma Treated with Bortezomib-Containing Multi-Agent Chemotherapy (2008) (4)
MRI-Detectable Focal Lesions (FL) in Multiple Myeloma (MM) at Relapse Frequently Involve Novel Sites Not Involved at Diagnosis. (2004) (4)
Atypical B12 Deficiency with Nonresolving Paraesthesia (2013) (4)
Infections After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation (2014) (4)
High-dose melphalan (MEL) based autotransplants (AT) for multiple myeloma (MM): The Arkansas experience since 1989 in more than 2,800 patients (2007) (4)
PET and PET/CT Imaging in Multiple Myeloma, Solitary Plasmacytoma, MGUS, and Other Plasma Cell Dyscrasias (2006) (4)
gamma-Cyclodextrin:testosterone complex suitable for sublingual administration. (1987) (4)
Immunomodulation for the treatment of invasive fungal infections. (1998) (4)
Erratum: International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia (European Journal of Clinical Microbiology and Infections Diseases (659) DOI: 10.1007/s10096-005-0024-8) (2006) (4)
Validation of a Novel Approach for Dose Individualization in Pharmacotherapy Using Gabapentin in a Proof of Principles Study (2013) (4)
Third Autotransplant for the Management of 98 Patients among 1358 Who Had Received Prior Tandem Autotransplants: Benefit Apparent When 2nd to 3rd Transplant Interval Exceeds 3 Years. (2004) (4)
AMPHOTERICIN B LIPID COMPLEX : RECENT PROGRESS (1996) (3)
Focus on Fungal Infections: Introduction and Comprehensive Summary (1992) (3)
Destruction of isolates from the Pittsburgh Veterans Affairs Laboratory. (2008) (3)
Single agent therapy for infections in cancer patients: A prospective randomized trial comparing three extended-spectrum cephalosporins (1991) (3)
Autophagy Is Uncoupled From ATG5-Dependent Apoptosis in Cells Resistant To Proteasome Inhibition (2013) (3)
Controversies in management of candidiasis in neutropenic patients treated for malignant diseases: new versus old or better versus worse (1997) (3)
Benefits of exercise in combination with epoetin alfa for multiple myeloma. (2006) (3)
Infectious Complications in Patients with Chronic Lymphocytic Leukemia (2008) (3)
Hematogenous candidiasis. A review of therapeutic studies of fluconazole and amphotericin B and recommendations for management (1995) (3)
A Randomized Placebo Controlled Phase II Trial of Prevention of Severe Oral Mucositis Using Single Dose Velafermin in Patients Receiving Myeloablative Therapy and Autologous Hematopoietic Stem Cell Transplant (AHSCT). (2007) (3)
Low Frequency of Treatment-Related Myelodysplastic Syndromes (t-MDS) after Autotransplants (AT) for Multiple Myeloma (MM), Especially If AT Is Applied Early during Treatment. (2005) (3)
Outcome of Invasive Aspergillosis (IA) in 30 Patients with Hematological Cancer (Hem-Ca): Immunity Is (Almost) Everything. (2006) (3)
Cullin-1 Controls The Clinical and Cellular response to Bortezomib Through NF-Kb Pathway Activation In Myeloma (2013) (3)
Clinical trial design for invasive aspergillosis: time to cast a different mold. (2009) (3)
Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: Analysis of multicenter Prospective Antifungal Therapy (PATH) alliance registry (Clinical Infectious Diseases (February 1, 2009) 48 (265-273)) (2009) (3)
A randomized trial of home-based exercise for patients receiving aggressive treatment and epoetin alfa for multiple myeloma: Hemoglobin (Hb), transfusion, fatigue and performance as outcomes. (2004) (3)
Modeling for Cure with Total Therapy (TT) Trials for Newly Diagnosed Multiple Myeloma (MM): Let the Math Speak. (2009) (3)
Erratum: Correlation between in vitro and in vivo activity of antifungal agents against Candida species (Journal of Infectious Diseases (August 1994) 170 (383 and 9)) (1994) (3)
Waldenström's Macroglobulinemia Associated with Serum Amyloid A Protein Amyloidosis: Pitfalls in Diagnosis and Successful Treatment with Melphalan-Based Autologous Stem Cell Transplant (2013) (3)
Metronomic chemoimmunotherapy in a patient with refractory Waldenström's macroglobulinemia (2005) (2)
18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET): An Important Tool in the Management of Infection in Patients with Hematological Cancer. (2004) (2)
Lack of Prognostic Implications of Induction Response to Total Therapy 2 (TT-2) in Newly Diagnosed Patients with Multiple Myeloma (MM) for Post-Transplant Even-Free Survival (EFS) and Overall Survival (OS). (2004) (2)
Cure fractions (CF) modeled from event-free survival and complete response duration plots in total therapy (TT) trials for newly diagnosed multiple myeloma (MM). (2010) (2)
Rapid Response to Treatment of Multiple Myeloma Detected with FDG PET Scanning in Multiple Myeloma - Early Results from Total Therapy III. (2004) (2)
Candida infections and candidemia. (1995) (2)
Far-reaching conclusions based on weak and missing data. (2012) (2)
Molecular Profiling of Multiple Myeloma Running Head: Molecular Analysis of Myeloma Section: Neoplasia (2001) (2)
SUPER- BEAM (SB): Incorporation of Bortezomib, Thalidomide, Dexamethasone, Cisplatin and Rapamycin Into the BEAM Regimen for Multiple Myeloma (MM). (2009) (2)
Reply to Koh and Luong and to Shaked et al (2010) (2)
Complete Response (CR) with Total Therapy 2 (TT2) for Multiple Myeloma (MM): Low Frequency in Case of Prior MGUS without Adverse Consequences for Survival - Yet Critical for Disease Control in Presumed “De Novo” MM. (2005) (2)
Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease (2021) (1)
High CD34 Yield Not Impaired by Melphalan 10mg/m2 Test-Dosing for Pharmacogenomics in M-VTD-PACE as Induction Therapy in Total Therapy 4 (TT4) for Low-Risk and Total Therapy 5 (TT5) for High-Risk Newly Diagnosed Multiple Myeloma (MM). (2009) (1)
The Transcriptome of Multiple Myeloma (MM) Defines Disease Subgroups with Distinct Genetic and Clinical Features. (2004) (1)
Emerging Fungal Infections (2005) (1)
Jumping Translocations 1q12 Contribute to Copy Number (CN) Alterations in Multiple Myeloma (MM): Unexpected Focal Amplifications of Receptor Chromosomes (RC) (2011) (1)
The Role of Plasma Cytokines in the Diagnosis of Autoimmune Phenomena in Patients (pts) With Multiple Myeloma (MM) Undergoing Novel Anti-Myeloma Therapies and Autologous Hematopoietic Cell Transplantation (auto-HCT) (2011) (1)
Predictors of deep vein thrombosis (DVT) in newly diagnosed multiple myeloma (MM) patients with and without prophylactic recombinant erythropoietin (EPO) therapy. (2009) (1)
Limitations of Guidelines in Every Day Management of Patients with Candida or Aspergillus Infections (2009) (1)
Candida Infections in the Intensive Care Unit (2002) (1)
Role of NonO 157 : H 7 Escherichia coli in Hemolytic Uremic Syndrome (2002) (1)
Correlation of Suppression of FDG PET Uptake with Serum Free Light Chain Levels - Both FDG PET-CT and Serum Clonal Free Light Chain Response Precede and Predict the Likelihood of Subsequent Complete Remission in Newly Diagnosed Multiple Myeloma. (2005) (1)
Primary plasma cell leukemia (PCL): Clinical and laboratory presentation and clinical outcome with total therapy (TT) protocols. (2010) (1)
Rapidly Cycled Aggressive Lymphoma-Like Therapy (HD-DTPACE) for Salvage of Patients with Advanced Multiple Myeloma (MM). (2006) (1)
Stenotrophomonas maltophiliameningitis Report of two cases and review of the literature (1997) (1)
Collection of Peripheral Blood Stem Cells in 668 Patients with Multiple Myeloma Treated on Total Therapy II (UARK 98-026). (2004) (1)
Analysis of Serial Body Height Measurements In Total Therapy 2 (TT2, Control v Thalidomide Arm) and Total Therapy 3 (A: VTD Maintenance; B: VRD Maintenance) as a Guide to Overall Bone Health In Multiple Myeloma (MM) (2010) (1)
Pretreatment Platelet Count Predicts the Outcome of Invasive Aspergillosis among Myeloma Patients Undergoing Myelosuppressive Chemotherapy (2008) (1)
A phase II, multicenter, randomized, double-blind, placebo-controlled trial of the safety and efficacy of velafermin (CG53135-05) administered intravenously as a single dose for the prevention of oral mucositis in patients receiving autologous hematopoietic stem cell transplant (AHSCT) (2006) (1)
Avascular Necrosis of Bone after Therapy for Multiple Myeloma: A Study of 561 Consecutive Patients. (2004) (1)
The Time Required To Achieve Complete Remission (CR) during Intensive Therapy on Total Therapy 2 Does Not Influence Event Free Survival (EFS), While Improvement in Quality of Response with Ongoing Treatment Clearly Does. (2005) (1)
Shorter Post-Relapse Survival (PRS) of Myeloma (MM) Patients Randomized to the Thalidomide (T) Arm of Total Therapy 2 (TT2) Related to Chromosome 1q21 Amplification (AMP1Q21, FISH) at Relapse. (2005) (1)
Total Therapy 3 Successor (TT3-S) Protocol (2006-66)–Confirming Results Reported for Initial TT3 (TT3-I) Protocol (2003-33) for Newly Diagnosed Multiple Myeloma (MM). (2009) (1)
Increased Bone Marrow Iron Stores, Severe Mucositis and Large Area under the Curve (AUC) of Profound Neutropenia Predict Severe Infection in 382 Myeloma Patients Undergoing Melphalan - Autologous Stem Cell Transplantation (MEL-ASCT). (2004) (1)
Treatment Associated Venous Thromboembolism (VTE) and Survival in Multiple Myeloma Patients. (2006) (1)
Safety of total therapy II with or without thalidomide (THAL) for newly diagnosed myeloma: A study of 475 consecutive patients (2003) (1)
Treatment of gram-negative bacteremia in patients with cancer and granulocytopenia. (1988) (1)
Total Therapy 2 (TT 2) for Newly Diagnosed Patients with Multiple Myeloma (MM): Examination of Dose Effect of Thalidomide (T) among Those Randomized to T. (2004) (1)
Prevention of Infections in Patients with Hematological Malignancies (2017) (1)
Predictive Biomarkers and Personalized Medicine Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR 3 C 1 (2012) (1)
Predicting Response to Therapy for Graft-vs-Host Disease (GvHD) with a Rapid Immune Function Assay. (2007) (0)
Total Therapy 2 (No Thalidomide Arm, TT2-) Is Superior to Total Therapy 1 (TT1) for Newly Diagnosed Multiple Myeloma (MM): Doubling 4-Yr Survival among Patients with Cytogenetic Abnormalities (CA) Due to Consolidation Chemotherapy (CCT) and DEX Maintenance. (2005) (0)
Arkansas Autotransplant (AT) Experience with > 2500 Myeloma (MM) Patients: Follow-Up Extending to >15 Years. (2005) (0)
in the context of global gene expression survival in multiple myeloma treated with Total Therapy I: interpretation especially of chromosome 13 and hypodiploidy, ensures long-term Continuous absence of metaphase-defined cytogenetic abnormalities, (2013) (0)
Targeting the Proteasome Pathway for the Treatment of Solid Tumors (2014) (0)
Fewer Pulls Required When Using a Powered Bone Marrow Biopsy System to Obtain Core Samples in the Multiple Myeloma Patients Population (2011) (0)
patients treated since 1989 stem-cell mobilization: the Arkansas experience in more than 3000 autotransplantation for multiple myeloma linked to poor hematopoietic Cytogenetically defined myelodysplasia after melphalan-based (2013) (0)
study of 169 patients single-agent thalidomide: identification of prognostic factors in a phase 2 Extended survival in advanced and refractory multiple myeloma after (2013) (0)
Diagnosis and Management of Recurrent Gastrointestinal Graft Versus Host Disease in Autologous Hematopoietic Stem Cell Transplantation: 718 (2009) (0)
Hyperbaric oxygen therapy for hematopoietic progenitor cell (HPC) collection in poor mobilizers. (2012) (0)
Weight Loss, CD-34 Cell Dose and Melphalan Dose More Than 5 Mg/Kg Independently Predicted Severe Complications in Patients with Myeloma Undergoing Transplant. (2012) (0)
Reply to Bergeron et al (2012) (0)
Stem cell transplantation for multiple myeloma-10 years later (2000) (0)
Reply to J. Mehta (2011) (0)
Chemotherapy-Induced Oral Mucositis: 11 SNPs Implicated In GWAS Of 972 Patients With Multiple Myeloma (2013) (0)
Absence of hypodiploidy and/or chromosome 13 abnormalities (hypo-CA13) confers superior survival in multiple myeloma (MM) patients (pts): Interim analysis of total therapy (TT) II trial (2003) (0)
High-Risk Multiple Myeloma Is Characterized by Uniform Over-Expression of Mirnas and Increased Copy Number and Expression of Argonaute 2 , A Master Regulator of Mirna Maturation and B-Cell Development. (2009) (0)
Diagnosis and Management of Recurrent Gastrointestinal Graft Versus Host Disease in Autologous Hematopoietic Stem Cell Transplantation (2009) (0)
Thrombotic Microangiopathy (TMA) Related to Cytomegalovirus (CMV) Is a Rare But Serious Condition After Autologous Hematopoietic Stem Cell Transplantation (ASCT) (2012) (0)
Super (S)-Beam for Advanced and Refractory Multiple Myeloma (ARMM) (2010) (0)
Incidence and Risk Factors for Lower Alimentary Tract Mucositis (neutropenic enterocolitis) Following 1528 Courses of Chemotherapy in a Homogenous Population of Myeloma Patients: Clinical and Research Implications. (2009) (0)
Management of Infectious Complications in Patients with Leukemia (2011) (0)
Plerixafor (P) plus G-CSF (G) in previous peripheral blood progenitor cell (HPC) mobilization failures (MF). (2009) (0)
Daily C - Reactive Protein (CRP) Levels Allow Early Identification of Patients with Severe Complications after Melphalan (MEL) and Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM). (2004) (0)
Post-Transplant Infectious Complications (IC) of Mannose-Binding Lectin (MBL)-Deficient Patients (pts) with Multiple Myeloma (MM) Who Received Recombinant Human MBL (rhMBL) Compared to Controls: A Retrospective Case-Control Study (2008) (0)
Effect on survival of treatment associated deep vein thrombosis in newly diagnosed multiple myeloma patients. (2006) (0)
Investigation of Discrepancies between Baseline MRI and PET-CT Studies in Patients with Newly Diagnosed Multiple Myeloma. (2005) (0)
Low Expression of Nuclear Glucocorticoid Receptor Gene NR3C1 in Newly Diagnosed Myeloma Correlates with Inferior Prognosis and Is Rescued by Thalidomide (2011) (0)
Prognostic implications of comprehensive imaging with PET-CT, MRI, and X-rays and their biological and molecular correlates in multiple myeloma (MM) treated with total therapy 3 (TT3). (2009) (0)
Incidence and Novel Risk Factors for Neutropenic Enterocolitis Following 1528 Courses of Chemotherapy in a Homogenous Cancer Population: 2009 ACG/AstraZeneca Senior Fellow Award, 2009 Presidential Poster (2009) (0)
prognosis to therapy define an aggressive multiple myeloma subtype with poor High serum-free light chain levels and their rapid reduction in response (2011) (0)
An unusual clinical course of cardiac Ig deposition disease (2009) (0)
Exercise to Relieve Cancer-Related Insomnia and Fatigue (2004) (0)
Total Therapy 2 (TT2) for Multiple Myeloma (MM): Contributions to Survival Outcomes of Dosing of Thalidomide (T), Dexamethasone (D) and Interferon (I) Maintenance Components. (2010) (0)
Immune Reconstruction Inflammatory Syndrome (IRIS) with Invasive Aspergillosis (IA) in Patients (pts) with Hematological Cancer (Hem-Ca): Clinical and Research Implications. (2006) (0)
Erratum: Mucosa or skin as source of coagulase-negative staphylococcal bacteraemia? (Lancet Infictious Diseases (2004) 4 (278-286)) (2004) (0)
Thanks to authors and peer reviewers (2007) (0)
Total Therapies (TT) for Newly Diagnosed Patients with Multiple Myeloma (MM): Significant Benefit in High-Risk Disease with Cytogenetic Abnormalities (CA) over the Course of 17 Years. (2006) (0)
Current Topic : Review vow . 8 , No . 4 (0)
thalidomide: implications for therapy Thrombogenic activity of doxorubicin in myeloma patients receiving (2013) (0)
The Conventional Body Surface Area (BSA) Method of Calculating the Dose of Melphalan (MEL) Results in Widely Variable MEL Exposure and Mucositis Risk in Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (ASCT). (2004) (0)
August 2003 (2003) (0)
Optimising the Use of Non-invasive Tests: From Blood to Radiology (2009) (0)
Total therapy 3 (TT3) for multiple myeloma (MM): Contributions to survival outcomes of dosing of maintenance components dexamethasone (D), thalidomide (T) and bortezomib (V). (2010) (0)
Erratum: Clinical research in the lay press: Irresponsible journalism raises a huge dose of doubt (Clinical Infectious Diseases (October 15, 2006) 43 (1031-1039)) (2007) (0)
variable in terms of both onset and duration in Total Therapy protocols Complete remission in multiple myeloma examined as time-dependent (2012) (0)
Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in HIV Positive Patients (PTS) in the Highly Active Antiretroviral Therapy (HAART) Era (2011) (0)
Reply to Pagano et al (2009) (0)
Methodological Limitations : Comparison of 2 Studies Evaluating the Role of Removal of Central Venous Catheters in Patients With Candidemia and / or Invasive Candidiasis (2012) (0)
DNA amplification and elevated expression of CKS1B is associated with reduced levels of p27Kip1 and poor survival in multiple myeloma (2005) (0)
Total Therapy 1 (TT1): Status Report of the First Tandem Autotransplant (TAT) Trial for Multiple Myeloma (MM) - 15 Years Later. (2005) (0)
Improving outcome of patients with invasive fusariosis: a cohort study from two major clinical registries (2012) (0)
Focal Lesion (FL) Identification by MRI and Metastatic Bone Survey (MBS) in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2 (TT2). (2006) (0)
Clinical Syndromes by Candida Species . . . . . . . . . . . . . . . . . . . Marı´a Cecilia Dignani (2005) (0)
Risk of Congenital Cytomegalovirus Infection (2005) (0)
Thalidomide and Hematopoietic Stem Cell Transplantation for Multiple Myeloma (2006) (0)
Fusarium infection, an emerging fungal pathogen: clinicopathologic study on 11 cases. (1990) (0)
BIOLOGY OF MULTIPLE MYELOMA: ONCOGENE ACTI- VATION IN THE GERMINAL CENTER, AND A CRITICAL ROLE FOR CYCLIN D DYSREGULATION MULTIPLE (2005) (0)
A Pseudoepidemic of Recent Tuberculin Test Conversions Caused by a Dosing Error (1996) (0)
cells gammopathy of undetermined significance, and normal bone marrow plasma Global gene expression profiling of multiple myeloma, monoclonal (2011) (0)
Bortezomib (BZB)-associated adverse events (AE) in patients with multiple myeloma (MM). (2011) (0)
Curing Multiple Myeloma: Lessons from Total Therapy Protocols (2009) (0)
Deregulated Cellular Iron Metabolism Factors Mediate Iron Overload in Myeloma Cells and Osteoclasts, and Promote Myeloma Growth and Bone Disease, (2011) (0)
Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis (2021) (0)
Prognosis in Multiple Myeloma (MM): Characterization of “Losers” (L) in Good Risk and “Winners” (W) in High Risk Disease. (2005) (0)
Autotransplants for Multiple Myeloma (MM) – An Update of the Arkansas Experience Since 1989 In Almost 4000 Patients with Special Emphasis on Third and Further Transplants. (2010) (0)
ORIGINAL ARTICLE Suppression of abnormal karyotype predicts superior survival in multiple myeloma (2008) (0)
Why outpatient therapy for fever during neutropenia? (1999) (0)
Individualizing the starting dose for MPT therapy in elderly myeloma patients. (2012) (0)
MRI and Metastatic Bone Survey (MBS) Examinations in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2. (2006) (0)
Superior 12-yr Survival (66% vs 30%) with 5-yr Continuous (Rc) vs “Discontinuous” Remission (Rd): Results of Total Therapies 1 & 2 (TT1,2) for Multiple Myeloma (MM). (2005) (0)
Abstracts of Original Contributions Cardiovascular Molecular Imaging Symposium May 3–4, 2004 Bethesda, Maryland (2004) (0)
Tuberculosis Drug Serum Levels (2010) (0)
Monitoring Immune Function in the Allogeneic Transplant Recipient: Predicting Graft vs Host Disease (GvHD) and Infection. (2007) (0)
Effect Of High Dose Chemotherapy And Autologous Stem Cell Transplantation On Pulmonary Function In Multiple Myeloma (2011) (0)
T1705 Neutropenic Enterocolitis and Clostridium difficile-Associated Disease in Cancer Patients Undergoing Chemotherapy: Lessons from a Homogeneous Population of Patients with Multiple Myeloma (2009) (0)
Relation of Anemia to Diastolic Heart Failure and the Effect on Outcome (2004) (0)
Randomized Phase 1B Study of Recombinant Human Mannose-Binding Lectin (rhMBL) (2008) (0)
The Arkansas experience with autotransplantation (AT) for older patients (OP, age > 65) with multiple myeloma (MM). (2010) (0)
Pacmed Salvage Therapy for Advanced High-Risk Multiple Myeloma (AHRMM) (2010) (0)
Safety of Total Therapy III for Newly Diagnosed Multiple Myeloma: Preliminary Analysis of 62 Consecutive Patients. (2004) (0)
Randomized, dose-defined, phase 1B study of recombinant human mannose-binding lectin (rhMBL, EZN-2232) in patients with multiple myeloma undergoing high-dose chemotherapy (2008) (0)
Fusarium infection - experimental model. (1990) (0)
The Immature Reticulocyte Fraction Predicts Marrow Recovery and Can Obviate the Need for Bone Marrow Examination in Persistently Neutropenic Cancer Patients (2011) (0)
Predicting Risk of Infection and Graft vs. Host Disease (GvHD), and Response to Immunosuppression (ISP) in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Patients (pts) Using the Cylex®ImmuKnow® Assay: A Pilot Study. (2006) (0)
Defining the prognostic variables in gene expression profiling (GEP)-defined high-risk multiple myeloma (MM): Distinguishing early failures (EF) from sustained control (SC). (2010) (0)
Testing Standard and Genetic Markers in 220 Patients with Multiple Myeloma (MM) with Complete Data Sets: Superiority of Molecular Genetics. (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Elias J. Anaissie?

Elias J. Anaissie is affiliated with the following schools:

University of Arkansas for Medical Sciences
University of Cincinnati
MD Anderson Cancer Center
Federal University of Rio de Janeiro
Virginia Commonwealth University
Pennsylvania State University
Lebanese University
University of Crete